For Visually Impaired, Early Offer of Low Vision Rehab May Be Best

This article originally appeared here.
Share this content:
For Visually Impaired, Early Offer of Low Vision Rehab May Be Best
For Visually Impaired, Early Offer of Low Vision Rehab May Be Best

MONDAY, Jan. 5, 2015 (HealthDay News) -- Several factors, including duration of symptoms, influence the decision to seek low vision rehabilitation services, according to a study published in the January issue of Ophthalmic & Physiological Optics.

Sarah A. Fraser, Ph.D., from McGill University in Montreal, and colleagues examined critical factors indicative of an individual's choice to access low vision rehabilitation services. A structured interview and questionnaires were administered to 749 visually impaired individuals. Seventy-five factors were assessed to determine awareness group: positive personal choice, negative personal choice, and lack of information.

The researchers found that making a positive personal choice to seek rehabilitation was indicated by having a response of moderate to no difficulty on item 6 (reading signs) of the Visual Function Index 14 (VF-14); having a great deal of difficulty on this item correlated with lack of information on low vision rehabilitation. Those who were more likely to have made a positive personal choice had symptom duration of under nine years, moderate difficulty or less on item 5 (seeing steps or curbs) of the VF-14, and little difficulty or less on item 3 (reading large print) of the VF-14. Males and those with greater difficulty on items 3 and 5 of the VF-14 were more likely to be in the lack of information group.

"The duration-of-symptoms factor suggests that, even in the positive choice group, it may be best to offer rehabilitation services early," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths